Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pure desmoplastic melanoma: a melanoma with distinctive clinical behavior.
Maurichi A, Miceli R, Camerini T, Contiero P, Patuzzo R, Tragni G, Crippa F, Romanidis K, Ruggeri R, Carbone A, Santinami M. Maurichi A, et al. Among authors: ruggeri r. Ann Surg. 2010 Dec;252(6):1052-7. doi: 10.1097/SLA.0b013e3181efc23c. Ann Surg. 2010. PMID: 21107116
Prediction of survival in patients with thin melanoma: results from a multi-institution study.
Maurichi A, Miceli R, Camerini T, Mariani L, Patuzzo R, Ruggeri R, Gallino G, Tolomio E, Tragni G, Valeri B, Anichini A, Mortarini R, Moglia D, Pellacani G, Bassoli S, Longo C, Quaglino P, Pimpinelli N, Borgognoni L, Bergamaschi D, Harwood C, Zoras O, Santinami M. Maurichi A, et al. Among authors: ruggeri r. J Clin Oncol. 2014 Aug 10;32(23):2479-85. doi: 10.1200/JCO.2013.54.2340. Epub 2014 Jul 7. J Clin Oncol. 2014. PMID: 25002727 Free article.
Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer.
Cavalieri S, Perrone F, Miceli R, Ascierto PA, Locati LD, Bergamini C, Granata R, Alfieri S, Resteghini C, Galbiati D, Busico A, Paielli N, Patuzzo R, Maurichi A, Gallino G, Ruggeri R, Mariani L, Palla M, Licitra L, Bossi P. Cavalieri S, et al. Among authors: ruggeri r. Eur J Cancer. 2018 Jul;97:7-15. doi: 10.1016/j.ejca.2018.04.004. Epub 2018 May 4. Eur J Cancer. 2018. PMID: 29734047 Clinical Trial.
Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.
Vergani E, Di Guardo L, Dugo M, Rigoletto S, Tragni G, Ruggeri R, Perrone F, Tamborini E, Gloghini A, Arienti F, Vergani B, Deho P, De Cecco L, Vallacchi V, Frati P, Shahaj E, Villa A, Santinami M, De Braud F, Rivoltini L, Rodolfo M. Vergani E, et al. Among authors: ruggeri r. Oncotarget. 2016 Jan 26;7(4):4428-41. doi: 10.18632/oncotarget.6599. Oncotarget. 2016. PMID: 26684239 Free PMC article.
Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma.
Di Guardo L, Randon G, Corti F, Vallacchi V, Raimondi A, Fucà G, Bini M, Maurichi A, Patuzzo R, Gallino G, Mattavelli I, Ruggeri R, Angi M, Cossa M, Valeri B, Cimminiello C, Santinami M, Rivoltini L, de Braud F, Rodolfo M, Vecchio MD. Di Guardo L, et al. Among authors: ruggeri r. Oncologist. 2021 Dec;26(12):1079-1084. doi: 10.1002/onco.13926. Epub 2021 Sep 21. Oncologist. 2021. PMID: 34355463 Free PMC article.
277 results